The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand ...

Inductive Bio has secured up to $21m in funding from ARPA-H to lead the development of AI drug-toxicity prediction models.

Counterfeit pharmaceuticals jeopardize public health worldwide, often leading to ineffective or dangerous treatments. Enter ...

In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions ( PTE ): Otsuka ...

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic ...

First and Only AI-Simulated Roleplay Solution Exclusively Designed for Pharmaceutical Field Professionals, Awarded for AI Roleplay and Field Simulation Excellence ...

GS Equity Income Fund underperformed in Q3. Discover key contributors like Oracle & J&J, and detractors Kenvue & Honeywell.

Nearly one in four European pharmaceutical companies remains vulnerable to regulatory risks due to inadequate quality systems ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...

Discover how the Goldman Sachs Equity Income Fund navigated Q3 2025's record highs and Fed uncertainty. Click here to read ...

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery ...